Classifications

• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
  • C09D133/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Coating compositions based on derivatives of such polymers
  • C09D133/04—Homopolymers or copolymers of esters
  • C09D133/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/28—Materials for coating prostheses
  • A61L27/34—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
  • A61L29/04—Macromolecular materials
  • A61L29/041—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
  • A61L29/08—Materials for coatings
  • A61L29/085—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/04—Macromolecular materials
  • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/08—Materials for coatings
  • A61L31/10—Macromolecular materials
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
  • C09D133/00—Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Coating compositions based on derivatives of such polymers
  • C09D133/04—Homopolymers or copolymers of esters
  • C09D133/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
  • C09D133/062—Copolymers with monomers not covered by C09D133/06
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
  • C12M23/00—Constructional details, e.g. recesses, hinges
  • C12M23/20—Material Coatings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
  • A61B10/02—Instruments for taking cell samples or for biopsy
  • A61B10/0233—Pointed or sharp biopsy instruments
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
  • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
  • A61B17/06066—Needles, e.g. needle tip configurations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B2017/00831—Material properties
  • A61B2017/00889—Material properties antimicrobial, disinfectant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B2017/00831—Material properties
  • A61B2017/00955—Material properties thermoplastic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B17/00—Surgical instruments, devices or methods
  • A61B2017/00982—General structural features
  • A61B2017/00995—General structural features having a thin film
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
  • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
  • A61F2/06—Blood vessels
  • A61F2/07—Stent-grafts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
  • A61L2300/606—Coatings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M25/00—Catheters; Hollow probes
  • A61M25/0043—Catheters; Hollow probes characterised by structural features
  • A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
  • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
  • A61M27/006—Cerebrospinal drainage; Accessories therefor, e.g. valves
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/178—Syringes
  • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N1/00—Electrotherapy; Circuits therefor
  • A61N1/02—Details
  • A61N1/04—Electrodes
  • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
  • A61N1/00—Electrotherapy; Circuits therefor
  • A61N1/02—Details
  • A61N1/04—Electrodes
  • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
  • A61N1/056—Transvascular endocardial electrode systems
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
  • C08F2438/00—Living radical polymerisation
  • C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
  • Y10T428/1334—Nonself-supporting tubular film or bag [e.g., pouch, envelope, packet, etc.]
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
  • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
  • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
  • Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article
  • Y10T428/1393—Multilayer [continuous layer]
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/31504—Composite [nonstructural laminate]
  • Y10T428/31551—Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
  • Y10T428/31645—Next to addition polymer from unsaturated monomers
  • Y10T428/31649—Ester, halide or nitrile of addition polymer
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/31504—Composite [nonstructural laminate]
  • Y10T428/31855—Of addition polymer from unsaturated monomers
  • Y10T428/31935—Ester, halide or nitrile of addition polymer

Definitions

• biocompatible material comprising a polymer coating consisting of or comprising poly(2-methoxyethyl acrylate) (PMEA) synthesized by Surface-Initiated Atom Transfer Radical Polymerization (Sl ATRP) such as ARGET (activator regenerated by electron transfer) SI ATRP or AGET (activators generated by electron transfer) SI ATRP and uses of said biocompatible material.
• PMEA poly(2-methoxyethyl acrylate) synthesized by Surface-Initiated Atom Transfer Radical Polymerization
• ARGET activator regenerated by electron transfer
• SI ATRP or AGET (activators generated by electron transfer) SI ATRP and uses of said biocompatible material.
• ATRP Atom Transfer Radical Polymerization
• the ATRP process was introduced by Matyjaszewski and Sawamoto [1-3] using different catalyst systems.
• ATRP is a controlled method which converts monomers to polymers by using radical polymerization.
• the initiators used for ATRP are commonly simple alkyl halides.
• a halogen atom X is transferred during the polymerization.
• a catalyst system is present which consist of a transition metal complexed by one or more ligands. The catalyst provides equilibrium between the active form and the inactive form (called the dormant state).
• a controlled polymerization method like ATRP will result in controlled molar masses, controlled polymer architecture, and narrow molecular weight distributions (cf. schematic illustration of ATRP in figure 1 ).
• P M EA polymers have previously been made by free radical polymerisation. Homopolymerization of MEA by ATRP has e.g. previously been described [9-11]. However, previously described PMEA coating is physically adsorbed to the surface whereas the PMEA made by SI ATRP such as ARGET SI ATRP or AGET SI ATRP according to the present invention is covalently bound to the surface. The covalent bonds result in a PMEA coating with improved characteristics such as improved long- term stability. Summary of invention
• the present invention relates to a polymer coating consisting of one or more repeating units of 2-methoxyethyl acrylate (MEA) covalently bound to one or more surface(s).
• MEA 2-methoxyethyl acrylate
• the invention relates to a PMEA coating obtained and/or obtainable by SI ATRP such as ARGET SI ATRP or AGET SI ATRP.
• the present invention relates to a device comprising one or more surface(s) covalently bound to repeating units of 2-methoxyethyl acrylate (MEA).
• Said device can be a container (such as a bottle, flask, box, bag, or ampoule), an implantable device (such as a stent, or pump), a tubing device, a membrane, a film, or a medical device (such as an infusion set, a dialysis device, a catheter or a pump).
• the present invention further relates to methods for making a PMEA coating by SI ATRP such as ARGET SI ATRP or AGET SI ATRP.
• SI ATRP such as ARGET SI ATRP or AGET SI ATRP method comprises one or more of the steps of
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s), 2-methoxyethyl acrylate and optionally one or more solvent(s) to a reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups o iii) allowing the reaction to take place; and optionally
• the present invention also relates to use of a coating of PMEA covalently bound to one or more surface(s).
• Said coating can be used for contacting one or more subject matters selected from the group consisting of one or more protein(s), one or more peptide(s), one or more body liquids, one or more tissues, and meat.
• the one or more body liquids can be selected from the group consisting of blood, blood plasma, serum, amniotic fluid, aqueous humour, cerumen, Cowper's fluid or pre-ejaculatory fluid, chyme, female ejaculate, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), pleural fluid, pus, saliva, sebum (skin oil), semen, sweat, tears, urine, vaginal secretion and vomit.
• the present invention also relates to use of a coating of PMEA covalently bound to one or more surface(s) for contacting such as during storage blood such as whole blood or fractions of blood.
• Blood fractionation is the process of fractionating whole blood, or separating it into its component parts. This fractionation can in one embodiment be performed by centrifugation of the blood.
• the resulting components of blood fractionation are in one embodiment:
• the buffy coat which is a thin layer of leukocytes (white blood cells) mixed with platelets in the middle
• the PMEA coating according to the present invention can be used for storage or contacting of any of these blood fractions or mixtures thereof.
• the PMEA coating according to the present invention can be used for storage or contacting of any of the following samples:
• Plasma protein(s) or plasma protein mixtures e.g. including albumin and/or, immunoglobulins, and/or clotting proteins such as fibrinogen.
• Plasma protein(s) or plasma protein mixtures for clinical use and/or therapeutic uses.
• Plasma components for clinical use such as factor VIII, factor IX complex, immunoglobulin, antithrombin III, alpha-l-antitrypsin
• the PMEA coating according to the present invention can be used for limitation or prevention of bacterial growth.
• the PMEA coating can be used for bacteria repelling.
• the PMEA coating can also be used for long terms as it has long term stability.
• the PMEA coating can e.g. be used for coating of a device used for long term storage of a suitable material (e.g. any of the materials mentioned in this application) for more than 1 months, more than 3 months, more than 6 months, more than 1 year, more than 5 years or more than 10 years with out significant leak of the
• PMEA coating into said material can in one embodiment mean that less than 5% of the PMEA coating is leaking into said material, such as less than 1 % or less than 0.1 %
• FIG. 1 Structure of poly(2-methoxyethyl acrylate) (PMEA).
• FIG. 4 Scheme showing the principle of Surface-Initiated ATRP (Sl ATRP).
• Figure 5 Example of preparation of initiating groups attached to surfaces of PEEK and PP, which can be used for SI ATRP
• ATRP is an abbreviation of Atom Transfer Radical Polymerization
• Biocompatible surface Material that, when interacting with biological material, does not disturb the biological material, e.g. without provoking a natural defensive response or e.g. does not induce an acute or chronic inflammatory response or e.g. does not prevent a proper differentiation of implant-surrounding tissues or e.g. does not affect the stability of proteins and/or peptides.
• Biocompatibility as used herein means the quality of not having toxic or injurious effects on biological systems.
• biocompatibility refers to the ability of a biomaterial to perform its desired function with respect to a medical therapy, without eliciting any undesirable local or systemic effects in the recipient or beneficiary of that therapy, but generating the most appropriate beneficial cellular or tissue response in that specific situation, and optimizing the clinically relevant performance of that therapy.
• Biomaterial Any material derived from a living entity including plants, animals and human beings or a living part thereof, such as an organ, tissue or cell.
• the preferred biological system is a mammalian system, preferably a human system.
• the biological material includes e.g. proteins, peptides and enzymes.
• Bodily fluids are liquids that are inside the bodies of animals or human beings. They include fluids that are excreted or secreted from the body as well as fluids that normally are not excreted or secreted from the body.
• Container can be any type of a container with a void cavity for storage (with or without a lid) such as a bottle, flask, bag, blood bag, pot, tub, dish, tray, bowl, basin, pill bottle, medicine bottle, ampoule, flagon, syringe, needle, tube, cell culture dish or flask, tissue culture dish or flask.
• a container with a void cavity for storage such as a bottle, flask, bag, blood bag, pot, tub, dish, tray, bowl, basin, pill bottle, medicine bottle, ampoule, flagon, syringe, needle, tube, cell culture dish or flask, tissue culture dish or flask.
• Fouling refers to the accumulation of unwanted material on a surface, e.g. in an aquatic environment.
• the fouling material can consist of either living organisms (biofouling) or a non-living substance (inorganic or organic).
• Other terms used in the literature to describe fouling include: deposit formation, encrustation, crudding, deposition, scaling, scale formation, and sludge formation. The last five terms have a more narrow meaning than fouling within the scope of the fouling science and technology.
• HMTETA is an abbreviation of 1 ,1 ,4,7,10,10-hexamethyltriethylenetetramine
• Implantable device as used herein, an implantable device may be any suitable medical substrate that can be implanted in a human or veterinary patient.
• MEA is an abbreviation of 2-methoxyethyl acrylate.
• a medical device is a product which is used for medical purposes in an animal or a human being in any type of diagnosis, treatment, therapy or surgery.
• Membrane Barrier between two phases and allowing transport via sorption/diffusion and/or through pores.
• PEEK is an abbreviation of poly(ether ether ketone)
• PMDETA is an abbreviation of 1 ,1 ,4,7,7-pentamethyldiethylenetriamine
• PMEA is an abbreviation of poly(2-methoxyethyl acrylate).
• PP is an abbreviation of polypropylene.
• Prosthesis is an artificial extension that replaces a missing body part.
• SI ATRP is an abbreviation of Surface-Initiated Atom Transfer Radical Polymerization. In one embodiment SI ATRP can be performed without use of a reducing agent.
• Normal SI ATRP refers to SI ATRP performed without use of a reducing agent.
• the term 'substrate' can be any material whereto the polymer according to the present invention can be covalently bound to the surface of said substrate.
• AGET activators generated by electron transfer.
• AIBN azobisisobutyronitrile.
• ARGET activator regenerated by electron transfer.
• ICAR initiators for continuous activator regeneration.
• RAFT reversible addition-fragmentation chain transfer.
• SR&NI simultaneous reverse and normal initiation.
• the present invention relates to a method for making a PMEA coating by SI ATRP (see figure 2 to 4) or ARGET SI ATRP (see figure 9).
• SI ATRP 2-methoxyethyl acrylate
• MEA is polymerized from one or more surface(s) and a polymer with the repeating unit shown in figure 2 is obtained. Accordingly, MEA is polymerized from one or more surface(s) with initiating o groups for ATRP and not in solution.
• the reaction kinetics for SI ATRP are different from those of ATRP.
• the invention relates to a PMEA coating obtained by and/or obtainable by SI ATRP such as ARGET SI ATRP or AGET SI ATRP.
• the present invention further relates to methods for making a PMEA coating by SI ATRP such as ARGET SI ATRP or AGET SI ATRP.
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s), 2-methoxyethyl acrylate and optionally one or more solvent(s) to a reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s) and optionally one or more solvent(s) to a first reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• said SI ATRP such as ARGET SI ATRP or AGET SI ATRP method comprises one or more of the steps of
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s), 2-methoxyethyl acrylate and optionally one or more solvent(s) to a reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• the one or more reducing agents are added to the reaction in excess.
• the one or more freeze-pump-thaw cycles used in the preparation of the PMEA coating can be 2, 3, 4, 5, 6, 7, 8 or more than 8 cycles of freeze-pump-thaw cycles.
• the reaction for generation of a PMEA coating by SI ATRP such as ARGET SI ATRP or AGET SI ATRP can take place at any temperature such as at from 20 ° C to 25 ° C , for example at from 25 ° C to 30 ° C, such as at from 30 ° C to 35 ° C , for example at from 35 ° C to 40 ° C, such as at from 40 ° C to 45 ° C , for example at from 45 ° C to 50 ° C, such as at from 50 ° C to 55 ° C, for example at from 55 ° C to 60 ° C, such as at from 60 ° C to 65 ° C , for example at from 65 ° C to 70 ° C, such as at from 70 ° C to 75 0 C , for example at from 75 ° C to 80
• the reaction for generation of a PMEA coating by SI ATRP can take place for any duration of time such as for 1 hour to 2 hours, for example for 2 hours to 3 hours, such as for 3 hours to 4 hours, for example for 4 hours to 5 hours, such as for 5 hours to 6 hours, for example for 6 hours to 7 hours, such as for 7 hours to 8 hours, for example for 8 hours to 9 hours, such as for 9 hours to 10 hours, for example for 10 hours to 11 hours, such as for 1 1 hours to 12 hours, for example for 12 hours to 13 hours, such as for 13 hours to 14 hours, for example for 14 hours to 15 hours, such as for 15 hours to 16 hours, for example for 16 hours to 17 hours, such as for 17 hours to 18 hours, for example for 18 hours to 19 hours, such as for 19 hours to 20 hours, for example for 20 hours to 21 hours, such as for 21 hours to 22 hours, for example for 22 hours to 23 hours, or such as for 23 hours to 24 hours or any combination thereof.
• the reaction can take place for any duration of time such as for 1 hour to
• reaction time for generation of a PMEA coating by SI ATRP such as ARGET SI ATRP or AGET SI ATRP determines the length and molecular weight of the polymer chains.
• the PMEA coating obtained by the SI ATRP method such as
• ARGET SI ATRP or AGET SI ATRP comprises chains of PMEA consisting of at least 5 MEA units, such as at least 10 MEA units, for example at least 15 MEA units, such as at least 20 MEA units, for example at least 25 MEA units, such as at least 30 MEA units, for example at least 35 MEA units, such as at least 40 MEA units, for example at least 45 MEA units, such as at least 50 MEA units, for example at least 55 MEA units, such as at least 60 MEA units, for example at least 65 MEA units, such as at least 70 MEA units, for example at least 75 MEA units, such as at least 80 MEA units, for example at least 85 MEA units, such as at least 90 MEA units, for example at least 95 MEA units, such as at least 100 MEA units, for example at least 200 MEA units, such as at least 300 MEA units, for example at least 400 MEA units, such as at least 500 MEA units, for example at least 600 MEA units, such as at least 700 MEA units, for example
• the PMEA coating can be polymerized from the surface of various substrates which means it will be covalently bound to the surface of said substrate [15].
• the one or more catalyst(s) can be selected from the group consisting of CuBr and CuCI.
• the metal ion in the catalyst is copper.
• the metal ion can be selected from the group consisting of ruthenium, iron, nickel, palladium, cobalt, rhodium, rhenium, osmium, titanium, lithium, molybdenum, and chromium.
• ruthenium, iron, nickel, palladium, cobalt, rhodium, rhenium, osmium, titanium, lithium, molybdenum, chromium and copper can work as catalyst in various complexes.
• other catalysts in combination with various ligands can be used.
• the one or more ligand(s) can be selected from the group consisting of 2,2'-bipyridine, 4,4'-dimethyl-2,2'-bipyridine, 5,5'-dimethyl-2,2'-bipyridine, 5,5'-isopropyl-2,2'-bipyridine, 5,5'-diheptyl-2,2'-bipyridine, 5,5'-ditridecyl-2,2'-bipyridine, 4,4'-di(5-nonyl)-2,2'- bipyridine (dNbpy), 1 ,10-Phenanthroline (1 ,10-Phen), 4,7-Diphenyl-1 ,10- phenanthroline, N,N,N',N'-tetramethylethylenediamine (TMEDA), 2,2':6',2"-terpyridine (tpy), 4,4',4"-tris(5-nonyl)- 2,2':6',2
• Cyclopropyldiazabutadiene (cyc/o-Pr-2), 1 ,4-Dihexyl-2,3-diphenylmethyl-1 ,4-diaza-1 ,3- butadiene, and ⁇ /-(n-Hexyl)-2-pyridylphenylmethanimine.
• the one or more solvents can be selected from the group consisting of water, ethanol, methanol, ethanol/water, methanol/water, toluene, propanol, isopropanol, butanol,
• the ethanol/water or methanol/water can in one embodiment be mixed in the following ratios (volume by volume) 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 2:1 , 3:1 , 4:1 , 5:1 , (0.1-1 ):1 , 1 :(0.1-1 ) or any other ratio.
• the ratio of solvent: MEA can be any ratio (volume by volume) such as (0.1-3):1 , for example (0.1-0.2):1 , such as (0.2-0.3): 1 , for example (0.3-0.4):1 , such as (0.4- 0.5):1 , for example (0.5-0.6):1 , such as (0.6-0.7):1 , for example (0.7-0.8):1 , such as (0.8-0.9):1 , for example (0.9-1.0):1 , such as (1.0-1.1 ):1 , for example (1.1-1.2):1 , such as (1.2-1.3):1 , for example (1.3-1.4):1 , such as (1.4-1.5):1 , for example (1.5-1.6):1 , such as (1.6-1.7):1 , for example (1.7-1.8):1 , such as (1.8-1.9):1 , for example (1.9- 2.0):1 , such as (2.0-2.1 ):1 , for example (2.1-2
• the ratio of MEA:solvent can be any ratio (volume by volume) such as (0.1 -3):1 , for example (0.1-0.2):1 , such as (0.2-0.3): 1 , for example (0.3-0.4):1 , such as (0.4- 0.5):1 , for example (0.5-0.6):1 , such as (0.6-0.7):1 , for example (0.7-0.8):1 , such as (0.8-0.9):1 , for example (0.9-1.0):1 , such as (1.0-1.1 ):1 , for example (1.1-1.2):1 , such as (1.2-1.3):1 , for example (1.3-1.4):1 , such as (1.4-1.5):1 , for example (1.5-1.6):1 , such as (1.6-1.7):1 , for example (1.7-1.8):1 , such as (1.8-1.9):1 , for example (1.9- 2.0): 1 , such as (2.0-2.1 ):1 , for example (2
• Polymeric or organic substrates Poly(ether ether ketone) (PEEK), Polypropylene (PP), Polyethylene (PE) (including linear low density polyethylene (LLDPE), low density polyethylene (LDPE) high density polyethylene (HDPE), ultra high molecular weight polyethylene (UHMWPE), and cross-linked polyethylene (PEX)), Poly(ethylene terephthalate) (PET), poly(propylene terephthalate (PPT), PPT/PET copolyester, Polybutylene terephthalate (PBT), Polyvinyl chloride) (PVC), Polyamide/nylon (PA), Polycarbonate (PC), Cyclic olefin copolymer (COC), Filter paper, Cotton, Cellulose, Poly(4-vinylbenzyl chloride) (PVBC), Poly(vinylidene fluoride) (PVDF), Polystyrene (PS), Toyopearl®, Hydrogels, Polyimide (Pl), 1 ,2-Pol
• poly(tetrafluoroethylene) PTFE
• Perfluoroethylene propylene copolymer FEP
• Ethylene tetrafluoroethylene copolymer ETFE
• Polyvinyl fluoride PVDF
• Polyvinylidene fluoride PVDF
• Polychlorotrifluoroethylene PCTFE
• PMMA poly(methyl methacrylate)
• ABS Acrylonitrile butadiene styrene
• ABS styrene acrylonitrile
• PAN Polyacrylonitrile
• PAN Polymethylpentene
• POM Polyoxymethylene
• PSU Polysulfone
• PSU polyetherimide
• PPO polyphenylene oxide
• PES polyethersulfone
• PPS Polyphenylene sulfide
• PAI Polyamideimide
• Liquid crystal polymer LCP
• Epoxy, Polyurethane PU
• TPE Thermoplastic elastomer
• Natural synthetic rubber comprises polyisobutylene (PIB), polyisoprene, poly(ethylene-co-propylene), Kraton polymers: Poly(styrene-b- butadiene-b-styrene) (SBS), poly(styrene-b-isoprene-b-styrene) (SIS), poly(styrene-b- (ethylene/butylene)-b-styrene) (SEBS), poly(styrene-b-(ethylene/propylene)-b-styrene) (SEPS).
• SBS Poly(styrene-b-butadiene-b-styrene)
• SIS poly(styrene-b-isoprene-b-styrene)
• SEBS poly(styrene-b-(ethylene/propylene)-b-styrene)
• Metallic or inorganic substrates Titanium, gold, glass, silicon, geranium, quartz, silicon oxide, silica, stainless steel, diamond, magnetic nanoparticles (e.g. Fe 3 O 4 ) etc.
• Nanoporous materials Membranes, Mesostructured cellular foam (MCF), and singlewall or multiwall Carbon Nanotubes (SWCNT, MWCNT).
• MCF Mesostructured cellular foam
• SWCNT singlewall or multiwall Carbon Nanotubes
• SI-ATRP Surface-Initiated Atom Transfer Radical Polymerization
• a standard ATRP initiating system is described in the background for the invention.
• Reverse ATRP involves in one embodiment in situ formation of Cu' from standard free radical initiators (e.g. AI BN) and Cu" salt which makes it less prone to oxidation problems and more useful for commercial applications.
• the transferable halogen atom is part of the copper salt in reverse ATRP i.e. ATRP initiator is not added; therefore, the catalyst concentration must be comparable to the concentration of the initiator.
• SR&NI ATRP a dual initiating system is present consisting of standard free radical initiators and initiators with a transferable atom or group.
• the radicals formed by AI BN are deactivated by an oxidatively stable Cu" salt in that way Cu' and some halogenated chains are generated.
• Cu' can reactivate the alkyl halide initiators and mediate normal ATRP.
• the ICAR ATRP method differs from SR&NI by use of a large excess of free radical initiator to catalyst. The radicals are slowly formed during the reaction and mechanistic studies have shown resemblance between the kinetics of ICAR and RAFT.
• AGET ATRP utilizes reducing agents which are unable to initiate new chains. The reducing agent reacts in one embodiment with the Cu" complex and forms the Cu' ATRP activator.
• Cu 0 , tin" 2-ethylhexanoate, ascorbic acid, and triethylamine have been reported as reducing agents for AGET ATRP.
• the present invention relates to ARGET ATRP wherein low concentration of catalyst to initiator is used.
• the coating of the present invention is a biocompatible coating e.g. compatible with biological material such as protein, peptide, body liquids such as blood, skin, tissue such as fatty tissue.
• the above mentioned inhibition of bacterial growth can be an inhibition of the bacterial growth with more than 50%, such as more than 60%, for example more than 70%, such as more than 80%, for example more than 90%, such as more than 95% or such as more than 99% compared to a surfaced that is not coated with PMEA.
• Another advantage is that there will be less leakage of the PMEA from a covalently bound PMEA coating than from a physically adhered PMEA coating. This can be an advantage e.g. for coatings on an implantable device. In one embodiment e.g. under moderate conditions there will be no leakage from the covalently bound PMEA coating.
• there will be less than 10% leakage such as less than 9%, for example less than 8%, such as less than 7%, for example less than 6%, such as less than 5%, for example less than 4%, such as less than 3%, for example less than 2%, such as less than 1 %, for example less than 0.5%, such as less than 0.1 %, for example less than 0.01 % leakage.
• a PMEA coating which is covalently bound to one or more surface(s) has an improved stability compared to a physically adhered PMEA coating.
• the SI ATRP such as ARGET SI ATRP or AGET SI ATRP methods are more specific and effective compared to the ATRP method for generation of a PMEA coating.
• the PMEA coating prepared by SI ATRP such as ARGET SI ATRP or AGET SI ATRP will lower the water contact angle of the substrate.
• the PMEA coating can be used in the area of biocompatible surface, i. e. those materials that are used in contact with living or dead tissue and biological fluids for prosthetic, therapeutic, diagnostics, storage or other applications.
• biocompatible surface i. e. those materials that are used in contact with living or dead tissue and biological fluids for prosthetic, therapeutic, diagnostics, storage or other applications.
• Many conventional biocompatible surfaces lack the ability to properly interact with or support biological matter coming into contact with said biocompatible surface leading to undesired biological responses.
• the PMEA coating can be used to produce a biocompatible surface e.g. for contact with e.g. one or more subject matters selected from the group consisting of one or more protein(s), one or more peptide(s), one or more liquid(s) comprising one or more protein(s), one or more liquid(s) comprising one or more peptide(s), one or more pharmaceuticals, one or more body liquids, one or more tissues, and meat.
• a biocompatible surface e.g. for contact with e.g. one or more subject matters selected from the group consisting of one or more protein(s), one or more peptide(s), one or more liquid(s) comprising one or more protein(s), one or more liquid(s) comprising one or more peptide(s), one or more pharmaceuticals, one or more body liquids, one or more tissues, and meat.
• the body liquids can in one embodiment be selected from the group consisting of blood, serum, blood plasma, amniotic fluid, aqueous humour, cerumen, Cowper's fluid or pre- ejaculatory fluid, chyme, female ejaculate, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), pleural fluid, pus, saliva, sebum (skin oil), semen, sweat, tears, urine, vaginal secretion and vomit.
• the PMEA coating can be used as a blood-contacting surface e.g. for a medical device.
• the PMEA coated biocompatible surfaces of substrates may thus be used as containers, cell-culture dishes, bioreactors, implants, biohybrid organs such as pacemakers, bioartificial pancreas, liver or kidney, and the like.
• the invention also pertains to the use of the PMEA coating in a method of controlling cellular growth and/or cellular proliferation and/or cellular differentiation in vivo, or use of the material in a method of separating and/or isolating biological material in vivo, or use of the material in a method of controlling cellular growth and/or cellular proliferation and/or cellular differentiation ex vivo, or use of the material in a method of separating and/or isolating biological material ex vivo, or use of the material in a method of producing a biohybrid organ ex vivo, and the use of the material in the manufacture of an implantable organ or part thereof.
• the PMEA coating according to the invention may also be used as a carrier for a pharmaceutically active ingredient or a pharmaceutical formulation or composition.
• the invention also pertains to the following methods:
• Method of diagnosis carried out on the human or animal body comprising the steps of contacting said body with the PMEA coating according to the present invention, and detecting a signal generated directly or indirectly by said PMEA coating.
• the PMEA coating according to the present invention can be used for coating of a container.
• Said container can be used for storage of e.g. one or more subject matters selected from the group consisting of one or more protein(s), one or more peptide(s), one or more liquid(s) comprising one or more protein(s), one or more liquid(s) comprising one or more peptide(s), one or more enzymes, one or more pharmaceuticals, one or more body liquids, one or more tissues, meat, cells including bacteria and mammalian cells such as human cells.
• the container coated with the covalently bound PMEA coating can in one embodiment be used for storage of one or more body liquids.
• the body liquids can in one embodiment be selected from the group consisting of blood, serum, blood plasma, amniotic fluid, aqueous humour, cerumen, Cowper's fluid or pre-ejaculatory fluid, chyme, female ejaculate, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), pleural fluid, pus, saliva, sebum (skin oil), semen, sweat, tears, urine, vaginal secretion and vomit.
• the container coated with the PMEA coating of the present invention can be used for storage to prevent or limit bacterial growth inside said container. Accordingly, the coating can be used to inhibit and/or prevent non-specific fouling.
• the PMEA coating disclosed by the present invention can be used for coating of a container such as any container (with or without a lid) with a void cavity suitable for storage such as a bottle, flask, bag, blood bag, pot, tub, dish, tray, bowl, basin, pill bottle, medicine bottle, ampoule, flagon, syringe, needle, tube, cell culture dish or flask or tissue culture dish or flask, bioreactor, pipette tip, or Pasteur pipette.
• the lid can also be coated if needed.
• the invention relates to use of the PMEA coating for coating of a container that can e.g. be used for sampling in a laboratory during diagnostics such as a test tube, PCR tube, an eppendorf tube, a blood sample glass, or a conical test tube, tissue culture dish or flask, cell culture dish or flask, slides for microscopic inspection, chamber slide, biopsy needle.
• a container that can e.g. be used for sampling in a laboratory during diagnostics such as a test tube, PCR tube, an eppendorf tube, a blood sample glass, or a conical test tube, tissue culture dish or flask, cell culture dish or flask, slides for microscopic inspection, chamber slide, biopsy needle.
• a medical device including implantable devices
• the PMEA coating disclosed by the present invention can be used for coating of a medical device such as an implantable device such as a hip replacement or a stent.
• the medical device can be selected from the group consisting of a blood filter, a blood storage bag, a blood circuit, an indwelling needle, a catheter, a pump, an infusion set, a guide wire, a stent, an oxygenator, a dialyzer and an adhesive for tissues.
• the medical device can further be an apparatus used for blood collection such as a blood collection equipment consisting of a plastic hub, a hypodermic needle, and a vacuum tube.
• a blood collection equipment is an evacuated tube system, such as the BD Vacutainer system.
• the blood collection equipment comprises a syringe with a butterfly needle, which is a plastic catheter attached to a short needle.
• the blood collection equipment comprises one or more Vacuum tubes.
• the medical device can further be selected from the group consisting of, blood collection tubes, vacuum blood collection tubes, vacuum tubes, negative pressure blood taking tube, capillary blood collection tube, blood transfusion equipment, blood sample equipment, blood transfusion set, infusion set, blood collection needle, serum tube, plasma tube, blood tube, bidirectional blood needle, cardiopulmonary bypass circuits and oxygenators.
• the medical device can further be a drug delivery device.
• Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration. Such devices are used as part of one or more medical treatments.
• Drug delivery devices include, but are not limited to, the following:
• An autoinjector such as a dual-chamber autoinjector which is a medical device designed to deliver a single dose of a particular (e.g. life-saving) drug.
• Most autoinjectors are spring-loaded syringes.
• DES drug-eluting stent
• a coronary stent a scaffold placed into narrowed, diseased coronary arteries that slowly releases a drug e.g. to block cell proliferation.
• a Dry powder inhaler which is a device that delivers medication to the lungs in the form of a dry powder.
• DPIs can be used to treat respiratory diseases such as asthma, bronchitis, emphysema, COPD and diabetes mellitus.
• a needle-based injector e.g. computer-controlled, battery-powered medical drug delivery device e.g. for delivery of the recombinant human growth hormone somatropin.
• a needle-free injector drug delivery device which, instead of accelerating a liquid jet across the skin like other needle-free injectors, uses a solid dose.
• the dose itself is the delivery vehicle.
• a pen injector using short needles to deliver precise doses of e.g. insulin.
• An infusion pump infuses fluids, medication or nutrients into a patient's
• Intraject is a needle-free injector medical device (drug delivery device) which accelerates a liquid jet across the skin to deliver the dose. It is a needle-free, prefilled, single-use, disposable, subcutaneous drug injection system.
• a jet injector is a type of medical injecting syringe that uses a high-pressure narrow jet of the injection liquid instead of a hypodermic needle to penetrate the epidermis, the purpose being to reduce the pain associated with needle injection.
• the implantable device can be implanted in a patient to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion,
• a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion,
• claudication anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
• implantable devices include self-expandable stents, balloon- expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g.,
• the underlying structure of the device can be of virtually any design.
• the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
• cobalt chromium alloy ELGILOY
• stainless steel 316L
• high nitrogen stainless steel e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
• MP35N and MP20N are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, PA.
• MP35N consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
• MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
• Devices made from bioabsorbable or biostable polymers could also be used with the
• the device itself such as a stent, can also be made from the described inventive PMEA coating.
• implantable devices include pacemaker, hip replacement, stent, brain implant, breast implant, buttock implant, cochlear implant, dental implant, extraocular implant, Harrington implant, Microchip implant, Retinal implant, Subdermal implant, and transdermal implant.
• the medical device can also be one or more prostheses.
• Prostheses can be used to replace body parts lost by injury (traumatic) or missing from birth (congenital) or to supplement defective body parts.
• Artificial heart valves are in common use with artificial hearts and lungs seeing less common use but under active technology development.
• Other medical devices and aids that can be considered prosthetics include artificial eyes, palatal obturator, gastric bands, dentures, artificial limbs, artificial organs, artficial knee, Lower Extremity Prosthetics, Hip disarticulations prosthetics, Knee disarticulations prosthetics, Symes prosthetics.
• the PMEA coating according to the invention can also be used for coating of neuromotor prostheses or neurocognitive prostheses such as implantable
• neurocognitive brain-computer interfaces for treat of a condition and/or disease such as stroke, traumatic brain injury, cerebral palsy, autism, and Alzheimer's disease.
• the PMEA coating can also be used for coating of biosensors.
• Biosensors detect signals from the users nervous or muscular systems. Examples of biosensors include wires that detect electrical activity on the skin, needle electrodes implanted in muscle, or solid-state electrode arrays with nerves growing through them. One type of these biosensors are employed in Myoelectric prosthesis.
• the PMEA coating can be used for prevention and/or inhibition of infection associated with a medical device and/or implant.
• a tubing device
• the PMEA coating according to the present invention can be used for coating of a tube.
• the tubes can be any type of tube such as a tube made of glass or plastic.
• the tube can be used for transport of one or more subject matters selected from the group consisting of one or more protein(s), one or more peptide(s), one or more liquid(s) comprising one or more protein(s), one or more liquid(s) comprising one or more peptide(s), one or more enzymes, one or more pharmaceuticals, one or more body liquids such as blood, blood plasma or serum, one or more tissues, meat, cells including bacteria and mammalian cells such as human cells.
• the tube can e.g. be a tube of an infusion set or blood transfusion equipment.
• the tube can also be part of laboratory equipment such as a device for chromatographic separation.
• the PMEA coating according to the present invention can be used for coating of a catheter.
• the catheter is in one embodiment a tube that can be inserted into a body cavity, duct, or vessel.
• the catheter thereby allow drainage, injection of fluids, or access by surgical instruments.
• the catheter is a thin, flexible tube ("soft" catheter), though in some uses, it is a larger, solid (“hard”) catheter.
• the catheter can be left inside the body, either temporarily or permanently (referred to as an indwelling catheter).
• a permanently inserted catheter may be referred to as a permcath. Placement of the PMEA coated catheter into a particular part of the body can e.g. allow:
• brachial plexus a major nerve bundle such as the brachial plexus
• a central venous catheter is a conduit for giving drugs or fluids into a large-bore catheter positioned either in a vein near the heart or just inside the atrium.
• a Swan-Ganz catheter is a special type of catheter placed into the pulmonary artery for measuring pressures in the heart.
• An umbilical line is a catheter used in Neonatal Intensive Care Units (NICU) providing quick access to the central circulation of premature infants.
• a Touhy borst adapter is a medical device used for attaching catheters to
• a Quinton catheter is a double or triple lumen, external catheter used for
• the PMEA coating according to the present invention can be used for preparation of separation media such as a membrane or filter for selective separation or purification of specific biological components like proteins, peptides and cells from biological fluids.
• separation media can be any which is suited for immobilisation, separation etc. such as filters, membranes, ultrafiltration membranes, nanoporous membranes, anti- fouling membranes, Silicone-Based Membrane, nanofiltration membranes, blood purification membrane, Membranes for Reverse Osmosis Desalinization, Reverse osmosis membrane, Hollow Fiber Membranes, Ion-exchange membrane, beads, fibres, webs, sinters or sieves
• the separation media can be a filter medium for selectively removing components from biological fluids e.g. leucocytes from blood and blood products.
• the invention will e.g. enable the use of improved membranes for ensuring spatial separation of e.g. xenogenic and/or allogenic cells from the host immune system.
• Modifying membranes with the PMEA coating according to the present invention can reduce the amount of adsorption of biological material such as proteins, peptides or cells on the plane of the membrane and at the same time improve the
• the coating according to the present invention can further be used on anti-fouling membranes e.g. in sensors, pumps, bioreactors, desalination, dialyses, blood purification etc.
• the PMEA coating according to the present invention can also be used for coating of one or more films such as polymer film(s), single or multiple layer films, e.g. for food and/or feed packaging, pharmaceutical packaging, blood bags etc.
• the present invention is in one embodiment characterised by the items herein below. Items:
• a polymer coating comprising or consisting of polymer chains comprising or consisting of repeating units of 2-methoxyethyl acrylate, wherein said polymer chains are covalently bound to one or more surface(s) of one or more substrate(s).
• polymer coating according to item 1 wherein the polymer coating is obtained or obtainable by SI ATRP, reverse ATRP, SR and NI ATRP, ICAR ATRP, AGET ATRP and/or ARGET ATRP.
• polymer coating according to item 1 wherein said polymer chains comprises chains of PMEA consisting of at least 5 MEA units, such as at least 10 MEA units, for example at least 15 MEA units, such as at least 20 MEA units, for example at least 25 MEA units, such as at least 30 MEA units, for example at least 35 MEA units, such as at least 40 MEA units, for example at least 45 MEA units, such as at least 50 MEA units, for example at least 55 MEA units, such as at least 60 MEA units, for example at least 65 MEA units, such as at least 70 MEA units, for example at least 75 MEA units, such as at least 80 MEA units, for example at least 85 MEA units, such as at least 90 MEA units, for example at least 95 MEA units, such as at least 100 MEA units, for example at least 200 MEA units, such as at least 300 MEA units, for example at least 400 MEA units, such as at least 500 MEA units, for example at least 600 MEA units, such as at least 700 ME
• said polymer chains comprises chains of PMEA, wherein at least 50% such as at least 60%, for example at least 70%, such as at least 80%, for example at least 85%, such as at least 90%, for example at least 95%, such as at least 99% of the MEA chains consisting of at least 5 MEA units, such as at least 10 MEA units, for example at least 15 MEA units, such as at least 20 MEA units, for example at least 25 MEA units, such as at least 30 MEA units, for example at least 35 MEA units, such as at least 40 MEA units, for example at least 45 MEA units, such as at least 50 MEA units, for example at least 55 MEA units, such as at least 60 MEA units, for example at least 65 MEA units, such as at least 70 MEA units, for example at least 75 MEA units, such as at least 80 MEA units, for example at least 85 MEA units, such as at least 90 MEA units, for example at least 95 MEA units, such as at least
• a device comprising one or more surface(s) covalently bound to the polymer coating according any of to items 1 to 4.
• the device according to item 5 wherein said device can be selected from the group consisting of cell culture dishes or flasks, bioreactors, syringe, needle, biopsy needle, pipette tip, test tube, slide for microscopic inspection, medicine bottle or ampoule, bag, pouch, implantable device, stent, blood filter, blood storage bag, a blood sample glass or tube, blood filter, a blood circuit, infusion set, pump, a catheter, a pump, an oxygenator, prostheses, and biosensors.
• said device can be selected from the group consisting of cell culture dishes or flasks, bioreactors, syringe, needle, biopsy needle, pipette tip, test tube, slide for microscopic inspection, medicine bottle or ampoule, bag, pouch, implantable device, stent, blood filter, blood storage bag, a blood sample glass or tube, blood filter, a blood circuit, infusion set, pump, a catheter, a pump, an oxygenator, prostheses, and biosensors.
• ARGET SI ATRP or AGET SI ATRP are ARGET SI ATRP or AGET SI ATRP.
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s), 2-methoxyethyl acrylate and optionally one or more solvent(s) to a reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s) and optionally one or more solvent(s) to a first reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), 2-methoxyethyl acrylate and optionally one or more solvent(s) to a first reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• initiator groups covalently bound to one or more surface(s) of a substrate
• adding one or more catalyst(s), one or more ligand(s), 2-methoxyethyl acrylate and optionally one or more solvent(s) to a reaction container comprising one or more substrate(s) with one or more surface(s) comprising said initiator groups
• the reaction can e.g. be performed at 20 ° C, 25° C, 30 ° C, 35 ° C, 40 ° C, 45 ° C, 50 ° C, 55 ° C, 60 ° C, 65 ° C, 70 ° C, 75 0 C, 80 ° C, 90 ° C, 95 ° C, or 100 ° C, or any combination thereof.
• the one or more reducing agents can be selected from the group consisting of tin" 2-ethylhexanoate, ascorbic acid, triethylamine, a number of organic derivatives of hydrazine, phenol, sugar as well as inorganic species such as Sn" and Cu 0 .
• the one or more ligand(s) can be selected from the group consisting of 2,2'-bipyridine, 4,4'-dimethyl-2,2'- bipyridine, 5,5'-dimethyl-2,2'-bipyridine, 5,5'-isopropyl-2,2'-bipyridine, 5,5'-diheptyl-2,2'- bipyridine, 5,5'-ditridecyl-2,2'-bipyridine, 4,4'-di(5-nonyl)-2,2'-bipyridine (dNbpy), 1 ,10- Phenanthroline (1 ,10-Phen), 4,7-Diphenyl-1 ,10-phenanthroline, N, N, N', N'- tetramethylethylenediamine (TMEDA), 2,2':6',2"-terpyridine (tpy), 4,4',4"-tris(5-n
• DETA diethylenetriamine
• TETA triethylenetetramine
• HMTETA triethylenetetramine
• PMDETA 1,1 ,4,7,7-Pentamethyldiethylenetriamine
• MA 5 DETA MA 5 DETA
• Glyoxal diimine-type (GIIm-R) ligands, Haddletons ligands US6310149: N-(n-Pentyl)-2- pyridylmethanimine (n-Pen-1 ), N-Ethyl-2-pyridylmethanimine (Et-1 ), N-(n-Propyl)-2- pyridylmethanimine (n-Pr-1 ), N-(Cyclopropyl)-2-pyridylmethanimine (cyclo-Pr-1 ), N- (DETA), triethylenetetramine (TETA), 1 ,1 ,4,7,10,10- hexamethyltriethylenetetramine (HMTETA
• Cyclopropyldiazabutadiene (cyc/o-Pr-2), 1 ,4-Dihexyl-2,3-diphenylmethyl-1 ,4-diaza-1 ,3- butadiene, and ⁇ /-(n-Hexyl)-2-pyridylphenylmethanimine or any combination thereof.
• the one or more solvent(s) is selected from the group consisting of water, ethanol, methanol, ethanol/water, toluene, propanol, isopropanol, butanol, 1 ,1 ,1 ,3,3,3-hexafluoro-2-propanol.
• ratio of solvent:MEA can be any ratio (volume by volume) such as (0.1-3):1 , for example (0.1-0.2):1 , such as (0.2-0.3): 1 , for example (0.3-0.4):1 , such as (0.4-0.5): 1 , for example (0.5-0.6):1 , such as (0.6-0.7):1 , for example (0.7-0.8):1 , such as (0.8-0.9):1 , for example (0.9-1.0):1 , such as (1.0-1.1 ): 1 , for example (1.1-1.2): 1 , such as (1.2-1.3):1 , for example (1.3- 1.4):1 , such as (1.4-1.5):1 , for example (1.5-1.6):1 , such as (1.6-1.7):1 , for example
• the ratio of MEA:solvent can be any ratio (volume by volume) such as (0.1-3):1, for example (0.1-0.2):1, such as (0.2-0.3):1, for example (0.3-0.4):1, such as (0.4-0.5):1, for example (0.5-0.6):1, such as (0.6-0.7):1 , for example (0.7-0.8):1 , such as (0.8-0.9):1 , for example (0.9-1.0):1 , such as (1.0-1.1):1, for example (1.1-1.2):1, such as (1.2-1.3):1, for example (1.3- 1.4):1 , such as (1.4-1.5):1 , for example (1.5-1.6):1 , such as (1.6-1.7):1 , for example (1.7-1.8):1 , such as (1.8-1.9):1 , for example (1.9-2.0):1 , such as (2.0-2.1 ):1 , for example (2.1-2.2):1,
• MEA:catalyst:ligand can be any ratio (mole by mole) such as (30-1000):1:(1-3), for example (30-50):1:(1-3), such as (50-100):1:(1-3), for example (100-150):1:(1-3), such as (150-200): 1:(1 -3), for example (200-250): 1:(1 -3), such as (250-300): 1:(1 -3), for example (300-350): 1:(1 -3), such as (350-400): 1:(1 -3), for example (400-450): 1:(1 -3), such as (450-500): 1:(1 -3), for example (500-550):1:(1-3), such as (550-600):1:(1-3), for example (600-650): 1:(1 -3), such as (650-700): 1:(1 -3), for example (700-750): 1:(1 -3), such as (750-800)
• MEA:catalyst:ligand:reducing agent can be any ratio (mole by mole) such as
• catalyst:ligand:reducing agent can be any ratio (mole by mole) such as 1 :(1-500):(1- 500), for example 1 :(25-500):(1-500), such as 1 :(50-500):(1-500), for example 1 :(75- 500):(1-500), such as 1 :(100-500):(1 -500), for example 1 :(150-500):(1 -500), such as 1 :(200-500):(1-500), for example 1 :(250-500):(1 -500), such as 1 :(300-500):(1-500), for example 1 :(350-500):(1 -500), such as 1 :(400-500):(1 -500), for example 1 :(1-50):(1- 500), such as 1 :(1 -100):(1 -500), for example 1 :(1 -150):(1 -500), such as 1
• catalyst:reducing agent:ligand can be any ratio (mole by mole) such as 1 :(1-500):(1- 500), for example 1 :(25-500):(1-500), such as 1 :(50-500):(1-500), for example 1 :(75- 500):(1-500), such as 1 :(100-500):(1 -500), for example 1 :(150-500):(1 -500), such as 1 :(200-500):(1-500), for example 1 :(250-500):(1 -500), such as 1 :(300-500):(1-500), for example 1 :(350-500):(1 -500), such as 1 :(400-500):(1 -500), for example 1 :(1-50):(1- 500), such as 1 :(1 -100):(1 -500), for example 1 :(1 -150):(1 -500), such as 1
• MEA catalyst:ligand (equivalents; mole by mole) is (1-2000):1 :(0.1-50). OO
• the one or more substrate(s) is Polymeric or organic substrates. 46. The method according to any of items 13 to 45, wherein the one or more substrate(s) is selected from the group consisting of Poly(ether ether ketone) (PEEK), Polypropylene (PP), Polyethylene (PE) (including linear low density polyethylene (LLDPE), low density polyethylene (LDPE) high density polyethylene (HDPE), ultra high molecular weight polyethylene (UHMWPE), and cross-linked polyethylene (PEX)), Polyethylene terephthalate) (PET), polypropylene terephthalate (PPT), PPT/PET copolyester, Polybutylene terephthalate (P BT), Polyvinyl chloride) (PVC), Polyamide/nylon (PA), Polycarbonate (PC), Cyclic olefin copolymer (COC), Filter paper, Cotton, Cellulose, Poly(4-vinylbenzyl chloride)
• PEEK Poly(ether ether ketone)
• poly(tetrafluoroethylene) PTFE
• Perfluoroethylene propylene copolymer FEP
• Ethylene tetrafluoroethylene copolymer ETFE
• Polyvinyl fluoride PVDF
• Polyvinylidene fluoride PVDF
• Polychlorotrifluoroethylene PCTFE
• PMMA poly(methyl methacrylate)
• ABS Acrylonitrile butadiene styrene
• ABS styrene acrylonitrile
• PAN Polyacrylonitrile
• PAN Polymethylpentene
• POM Polyoxymethylene
• PSU Polysulfone
• PSU polyetherimide
• PPO polyphenylene oxide
• PES polyethersulfone
• PPS Polyphenylene sulfide
• PAI Polyamideimide
• Liquid crystal polymer LCP
• Epoxy, Polyurethane PU
• TPE Thermoplastic elastomer
• the one or more substrate(s) is selected from the group consisting of titanium, gold, glass, silicon, geranium, quartz, silicon oxide, silica, stainless steel, diamond , and magnetic nanoparticles (e.g. Fe 3 O 4 ).
• the one or more substrate(s) is one or more Nanoporous materials.
• the one or more substrate(s) is one or more membranes.
• the one or more substrate(s) is one or more singlewall or multiwall Carbon Nanotubes (SWCNT, MWCNT).
• the one or more substrate(s) is one or more materials with functional groups which can be used directly for attaching the initiating groups.
• a polymer coating comprising or consisting of polymer chains comprising or consisting of repeating units of 2-methoxyethyl acrylate, wherein said polymer chains are covalently bound to one or more surface(s) of one or more substrate(s) and wherein said polymer coating is obtained or obtainable by the method according to any of items 13 to 54.
• any of items 1 to 4 and 55 for contacting one or more subject matters selected from the group consisting of one or more protein(s), one or more peptide(s), one or more pharmaceutical(s), one or more body liquids, one or more living or dead tissues, skin, fatty tissue and meat.
• the one or more body liquids can be one or more body liquids selected from the group consisting of blood, blood plasma, serum, amniotic fluid, aqueous humour, cerumen, Cowper's fluid or pre-ejaculatory fluid, chyme, female ejaculate, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), pleural fluid, pus, saliva, sebum (skin oil), semen, sweat, tears, urine, vaginal secretion and vomit.
• body liquids selected from the group consisting of blood, blood plasma, serum, amniotic fluid, aqueous humour, cerumen, Cowper's fluid or pre-ejaculatory fluid, chyme, female ejaculate, interstitial fluid, lymph, breast milk, mucus (including nasal drainage and phlegm), pleural fluid, pus, saliva, sebum (skin oil), semen, sweat, tears, urine, vaginal secretion and vomit.
• FIG. 1 Scheme showing the principle of Atom Transfer Radical Polymerization (ATRP). It is a controlled method which converts monomers (M) to polymers (P) by using radical polymerization.
• the initiators used for ATRP are commonly simple alkyl halides.
• a halogen atom X is transferred during the polymerization.
• a catalyst system is present which consist of a transition metal (M t x ) complexed by one or more ligands (X-M t x+1 /Ligand). The catalyst provides equilibrium between the active form, P m * and the inactive form, P n -X (called the dormant state).
• the equilibrium is displaced towards the dormant state; therefore, the polymer chains will only be active for a short time, thus allowing for a suppression of chain termination reactions and thereby controlling the polymerization.
• a controlled polymerization method like ATRP will result in controlled molar masses, controlled polymer architecture, and narrow molecular weight distributions.
• the rate constants for the activation, deactivation, propagation and termination are: k act , k de act, k p , and k t .
• Figure 2 Structure of poly(2-methoxyethyl acrylate) (PMEA).
• PMEA poly(2-methoxyethyl acrylate)
• FIG. 3 Preparation of poly(2-methoxyethyl acrylate) (PMEA).
• PMEA poly(2-methoxyethyl acrylate)
• R-X is the initiator for ATRP and it consists of an alkyl halide; R is the alkyl and X is the halide (chlorine or bromine).
• the catalyst system for the polymerization reaction is e.g. CuBr or CuCI and one or more ligands e.g.
• 2,2'-bipyridine (Bipy), 1 ,1 ,4,7,10,10- hexamethyltriethylenetetramine (HMTETA), or 1 ,1 ,4,7,7-pentamethyldiethylenetriamine (PMDETA).
• solvents are listed water (H 2 O) or ethanol (EtOH) or a mixture of ethanol and water (EtOH:H 2 O) or toluene.
• the polymerization takes place at a temperature between 20 and 95 0 C.
• the polymerization time is between 1 and 24 hours, n is the number of repeating units in PMEA.
• FIG. 4 Explanation of the technique Surface-Initiated Atom Transfer Radical Polymerization (Sl ATRP). If hydroxyl groups are present they can be used for coupling the initiating groups for ATRP. Otherwise the surface of the substrate(s) needs to be activated in order to form functional groups which can be used for the coupling reaction. After anchoring of the initiating groups SI ATRP can take place.
• the polymerization reaction is an equilibrium between an active form and an inactive form and the inactive form is the favourable state.
• M t 7l_igand or X-M t x+1 /Ligand is the catalyst system on either side of the equilibrium. When the polymer chains are active the atom X (chlorine or bromine) will bound to the catalyst.
• the last step is rinsing the
• Figure 5 Example of preparation of initiating groups on poly(ether ether ketone) (PEEK).
• ketone groups in PEEK will be reduced to hydroxyl groups by reaction with sodium borohydride (NaBH 4 ) in dimethyl sulfoxide (DMSO) for 3 hours at 120 0 C.
• n is the number of repeating units in PEEK.
• the hydroxyl groups on PEEK are transformed into initiating groups for SI ATRP by using 2-bromoisobutyryl bromide (Br-iBuBr) in the presence of 4-dimethylaminopyridine (DMAP) and triethylamine (TEA) in tetrahydrofurane (THF). The reaction takes place within 18 hours.
• Br-iBuBr is added the temperature should be kept at 0 0 C.
• Br-iBuBr is added the temperature in the reaction mixture will increase. The reaction mixture is left without cooling and the temperature will reach room temperature (rt).
• the PMEA coating contains e.g. ester groups and ether groups which the substrate PP does not.
• the C-O stretching band from the ether groups of PMEA is at 1131 cm “1 ).
• Figure 8 A) Water contact angle (WCA) measurements on substrates coated with PMEA prepared by ATRP.
• the advancing WCA of unmodified Liquid Silicon Rubber (LSR) is 120° and it is lowered to 69° when coated with PMEA.
• LSR Liquid Silicon Rubber
• LDPE low density polyethylene
• the advancing WCA is 90° and coated with PMEA it is 50°.
• the static WCA of poly(methyl methacrylate) (PMMA) is changed from 82° to 51° when o coated with PMEA.
• WCA Water contact angle
• the advancing WCA decreases from 106° to 78° whereas the receding WCA is reduced from 90° to 41° when MEA is polymerized from PP.
• advancing and receding are abbreviated adv. and rec. respectively.
• Activator regenerated by electron transfer (ARGET) SI ATRP differs from SI ATRP in lower amount of catalyst and ligand and presence of reducing agent.
• Cu is applied instead of Cu'.
• the polymerization reaction is an equilibrium between the dormant state (surface-X) and the active form (surface- * ). When the chains are active another monomer is added (+M).
• Cu is continuously reduced by the reducing agent to Cu'.
• the copper catalyst contains X (chlorine or bromine) and is complexed by a ligand.
• the rate constants for the activation, deactivation, and propagation are: k a , k d , and k p .
• a reactor was charged with catalyst, ligand and substrates as well as half of the solvent if the polymerization was not done in bulk.
• inert atmosphere e.g. nitrogen or argon gas
• the solvent could also be added to one of the tubes instead of dividing it into the two tubes.
• the ligand is not a liquid; some solvent or monomer should be used to wet the catalyst system in order to avoid removal of the catalyst system during degassing. If monomer is used for the wetting; catalyst and ligand should not be in the same reactor/tube.
• catalyst systems comprise catalysts, wherein the metal in the catalyst is copper. However, the metal in the catalyst does not necessarily have to be copper. Other catalysts in combination with various ligands can be used.
• PEEK contains ketones which can be reduced to hydroxyl groups by NaBH 4 in dimethyl sulfoxide (DMSO) [10] (see figure 5A).
• initiating groups can be formed by modifying the hydroxyl groups with 2- bromoisobutyryl bromide (Br-iBu Br) i n the presence of 4-dimethylaminopyridine (DMAP) and triethylamine (TEA) in tetrahydrofurane (THF) (see figure 5B).
• DMAP 4-dimethylaminopyridine
• THF tetrahydrofurane
• PP is on the other hand a very inert material which can be activated by e.g. irradiation, plasma treatment etc.
• irradiation e.g. irradiation, plasma treatment etc.
• One procedure is immersion of PP in a solution of toluene and 4- hydroxy benzophenone (BP-iBuBr) followed by UV irradiation at 365 nm. C-C bonds will be formed between PP and the carbon marked with a star ( * ) [1 1] (see figure 5C).
• SI-ATRP can be performed with e.g. MEA using the conditions described above (see Figure 5D).
• Figure 5D For other none limiting examples see [12-13].
• Staphylococcus aureus S. aureus
• Staphylococcus epidermidis Pseudomonas aeruginosa
• the bacterial attachment is substantially reduced by the PMEA coating disclosed in the present invention.
• Staphylococcus epidermidis biofilm formation is reduced by 95% (see figure 6A-D).
• Figure 6A shows the S. aureus static adherence results based on 3 hours and 24 hours on control and PMEA coated glass slides, respectively ( Figure 6A). This demonstrates less adherence of S. aureus to the PMEA coated glass slide.
• Figure 6B shows Staphylococcus epidermidis bacterial attachment on control and PMEA coated glass slides, respectively ( Figure 6B).
• the PMEA coated plate has less bateria attachment.
• Figure 6C shows Staphylococcus epidermidis (down pictures) attachment (24 hours biofilm formation) to 96 well plates ( Figure 6C).
• the PMEA coating has less attachment of Staphylococcus epidermidis.
• S. aureus incubated for 24 hours at 37 0 C shows 90% reduction of S. aureus biofilm formation for the PMEA coated plate compared to the control plate ( Figure 6D).
• Example 5 Attenuated Total Reflectance Fourier Transform Infrared (ATR FT-IR) spectroscopy
• Attenuated Total Reflectance Fourier Transform Infrared (ATR FT-IR) spectroscopy of the PMEA coating according to the present invention (see result in figure 7; Green represents Unmodified PP, Red represents PMEA grafted from PP using CuBr/BiPy in Methanol/water 1 :1 , Blue represents PMEA grafted from PP using CuBr/HMTETA in bulk and Black represents PMEA grafted from PP using CuBr/PMDETA in bulk) and figure 8A).
• Attenuated Total Reflectance (ATR) Fourier Transform Infrared (FTIR) spectra were obtained using a Spectrum One spectrometer from Perkin Elmer which was equipped with a universal ATR sample accessory.
• the water contact angle (WCA) measurements on PMEA prepared by ATRP and coated on different substrates are shown in figure 8A.
• the method can be used to determine the hydrophilicity of PMEA coated substrate.
• the measurements shown are made with either a dynamic method which gives advancing and receding angles or a static method which only gives one value.
• advancing angles will be sensitive to the hydrophobic domains and receding angles will characterize the hydrophilic domains on the surface.
• the difference between the advancing and receding CA can be used to help characterize surface heterogeneity and roughness.
• the measurements in figure 8B were made on OCA20 Contact Angle System from Dataphysics with a temperature controller. The temperature was set to 25 0 C. A dynamic method called “sessile drop (needle in)" was used and the WCAs were computed using "Ellipse Fitting”.
• PMEA has been grafted from polypropylene (PP) using SI-ATRP. Different catalyst systems have been used which have resulted in different water contact angles (see table below).
• the PMEA coated PP (PP-g-PMEA) in italic is used for the pictures in figure 8B.
• HMTETA 1 ,1 , 4,7,10,10-Hexamethyltriethylenetetramine
• the WCAs are lowered when PMEA is grafted from the surface of PP substrates. Especially the receding WCAs are lower for the modified PP compared with the unmodified PP due to changes in the hydrophilicity. It is shown in the table that the polymerization conditions e.g. the catalyst systems have an influence on the WCAs of PP-g-PMEA as they can affect the grafting densities and chain lengths.
• Example 7 ARGET SI ATRP of MEA with low catalyst concentration
• ARGET SI ATRP of MEA was performed from 188 PP plates (3.5 x 0.6 x 0.1 cm each).
• the PP plates were functionalized with initiating groups for ATRP (see example 3) prior to the grafting of PMEA.
• the plates, CuBr 2 (21.1 mg), Me 6 TREN (213.6 mg), L-ascorbic acid (164.0 mg), 120 ml. anisole, and a stirring bar were added to a round-bottom flask.
• MEA 180 ml. was added to another round-bottom flask. Two freeze-pump-thaw cycles were carried out for each flask and MEA was transferred to the other flask.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Chemistry (AREA)
• Vascular Medicine (AREA)
• Surgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Dermatology (AREA)
• Materials Engineering (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dentistry (AREA)
• Plant Pathology (AREA)
• Pest Control & Pesticides (AREA)
• Agronomy & Crop Science (AREA)
• Environmental Sciences (AREA)
• Microbiology (AREA)
• General Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Immunology (AREA)
• Sustainable Development (AREA)
• Biochemistry (AREA)
• Clinical Laboratory Science (AREA)
• Genetics & Genomics (AREA)
• Paints Or Removers (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Materials For Medical Uses (AREA)
• Polymerisation Methods In General (AREA)

Priority Applications (5)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (2)

Family

ID=41269072

Family Applications (1)

Country Status (5)

Cited By (4)

Families Citing this family (28)

Citations (2)

Family Cites Families (16)

• 2010
  • 2010-07-14 JP JP2012519886A patent/JP5872465B2/ja not_active Expired - Fee Related
  • 2010-07-14 WO PCT/DK2010/050187 patent/WO2011006507A2/en not_active Ceased
  • 2010-07-14 US US13/384,130 patent/US9346971B2/en not_active Expired - Fee Related
  • 2010-07-14 DK DK10799454.3T patent/DK2453942T3/en active
  • 2010-07-14 EP EP10799454.3A patent/EP2453942B1/en not_active Not-in-force
• 2016
  • 2016-05-20 US US15/160,150 patent/US20170044392A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events